Skip to NavigationSkip to content

Business Services

Top Ten most popular articles on this week!

Pfizer dominated the headlines this week as the US firm closed its $9.8 billion merger with GSK and announced that it would be combining its off-patent drug unit with Mylan. The news came as Sanofi sought to end its partnership with Lexicon after the release of new data for diabetes drug Zynquista.

The patient is always right: Extracting the full value of PROMs

Published on 29/07/19 at 11:52am

Patient-reported outcomes measures are an invaluable tool in ensuring that the patient remains in the driving seat when it comes to their own care. But are they really hitting the mark in today’s healthcare systems? Matt Fellows investigates...

The traditional model of healthcare, particularly in the UK, has calcified over time into a train of decision-making where the most important voice – the patient’s themselves – has been largely excluded from the key discussions.

Top Ten most popular articles on this week

At the end of a week that could certainly be called "eventful" here in the UK - one that saw Conservative MP Boris Johnson take the country's top job after securing votes from less than 1% of the population - a number of big stories have emerged from the industry.

Among them is the great news that nine new generic versions of Pfizer's Lyrica will now be made available across the US, and the promising announcement that UK watchdog NICE is to review its sometimes-maligned decision-making process.

Vertex promote chief medical officer to CEO as Jeffrey Leiden steps down

Published on: 25/07/19

Dr Reshma Kewalramani has been made the new Vertex CEO.

Vertex’s Chief Medical Officer Dr Kewalramani will succeed current CEO Jeffrey Leiden who has is now stepping aside from the role after seven years as Chief executive at the Boston-based firm. In stepping down Leiden will serve as executive chairman until the first quarter of 2023.     

Fourty-six year old Dr Kewalramani, who has been at Vertex since 2017, will thus become the first woman to head the firm. Prior to joining Vertex, Kewalramani spent more than 12 years at Amgen.

Christi Shaw taken on by Gilead as Kite Pharma's new CEO

Published on: 25/07/19

Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO.

Shaw comes to Gilead’s cancer immunotherapy firm, Kite Pharma, from rival US firm Eli Lilly, where she acted as a senior vice president and also as president of Lilly’s immunology, pain and neuroscience unit, Lilly Bio Medicines.

Elizabeth Warren calls on Albert Bourla to reveal detail of appointment of former FDA commissioner Scott Gottlieb to Pfizer's board

Elizabeth Warren has called on Pfizer to reveal the details of Scott Gottlieb’s appointment to the company’s Board of Directors.

GSK hire Jonathan Symonds as new Chairman

Published on: 24/07/19

Business chief Jonathan Symonds has joined British multinational GlaxoSmithKline as the company’s new non-executive chairman.

The hire ends GSK’s six month search, as it prepares to fold its consumer business into a joint venture with Pfizer. In his new role Symonds will oversee the changes being implemented by CEO Emma Walmsley who joined GSK in 2017. Walmsley hopes to revitalise GSK’s R&D efforts with the help of Chief Scientific Officer Hal Barron.

ABPI Chief Executive Mike Thompson to retire by the end of 2019

Published on: 24/07/19

Chief Executive Mike Thompson is to retire from his role at the Association of the British Pharmaceutical Industry (ABPI) by the end of this year.

His decision to leave the association marks the end of a three-year run beginning in March 2016, when stepped in to take up the mantle from Alison Clough, who had served as the acting Chief Executive for much of 2015.

Disarm Therapeutics hires Dr Alvin Shih as new President and CEO

Published on: 23/07/19

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO.

The Cambridge, Mass.-based firm has set itself the task of creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central drive of neurological disease.

Dr Shih brings to the role a range of experiences. Having graduated with a biology degree from Vanderbilt University in 1996, Shih joined management consultancy McKinsey where he worked as a business analyst for two years.

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world

Published on 22/07/19 at 10:25am

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been sacrificed in the pursuit of bottom level prices. Louis Goss talks to investigative journalist Katherine Eban as she discusses the realities of the generic drug industry today.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches